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Background: Ulcerative colitis (UC) is the most common form of inflammatory bowel disease in the USA. A key
component of UC is the increase in inflammatory angiogenesis of the colon during active disease. This increase is
driven to a great extent by the over expression of VEGF-A. Recently, VEGF165b (VEGF164b in mouse), an anti-
angiogenic form of VEGF-A was described and its regulation was determined to be disturbed in many pathologies
such as cancer and pre-eclampsia.
Results: The aims of this study were to examine the role of this inhibitory VEGF by expressing this molecule in a
model of intestinal inflammation, and to evaluate its expression as a potential new therapeutic approach for
treating UC. A modified model of TNBS colitis was used to determine the effects of rVEGF164b expression on colon
inflammation. Expansion of the vascular system was assessed by immunhistochemical methods and macro- and
microscopic measurements of inflammation in the colon were measured. Leukocyte invasion of the tissue was
measured by myeloperoxidase assay and identification and counting of lymphoid follicles. Both angio- and
lymphangiogenesis were reduced by expression of rVEGF164b, which correlated with reduction in both gross and
microscopic inflammatory scores. Leukocyte invasion of the tissue was also reduced by rVEGF164b expression.
Conclusions: This is the first report using an endogenous inhibitory VEGF-A isoform for therapy in a model of
experimental colitis. Inhibitory VEGF molecules play an important role in maintenance of gut homeostasis and
may be dysregulated in UC. The results of this study suggest that restoration of rVEGF164b expression has
anti-inflammatory activity in a TNBS model and warrants further examination as a possible therapeutic for UC.
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Ulcerative colitis (UC) is a complex intestinal inflamma-
tory disorder that reflects complex interactions between
gut tissue, circulating and tissue resident immune cells,
gut flora and the vascular system. Data from the Na-
tional Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK) shows that UC is responsible for 244
out of every 100,000 diagnoses and 28 out of every
100,000 hospital admissions. Total cost burden for UC* Correspondence: jmathi@lsuhsc.edu
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reproduction in any medium, provided the orprescriptions is greater than that of Crohn’s disease
($272 million compared with $261 million); this excludes
costs for hospital visits [1,2]. Besides the cost of treat-
ment, the impact of UC on quality of life is staggering,
and includes increased susceptibility to infection, com-
plications from side effects of therapeutic drugs, and an
increased risk for developing colorectal cancer [3-5].
Angiogenesis in the colon during UC results in in-
flamed vessels that support disease activity and progres-
sion through recruitment of immune cells, secretion of
inflammatory mediators and increased microvascular
and epithelial permeability [6,7]. The increase in the
blood vessel density that accompanies UC is predictive
of the severity of disease. Inhibition of intestinalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tective against experimental colitis [8,9]. VEGF-A, a key me-
diator of angiogenesis in UC, has been found to be up
regulated in the sera of UC patients and in animals with
experimental UC [10,11]. Experiments in animal models
of UC have shown that inhibiting VEGF-A signaling can
attenuate disease activity while increased levels of VEGF-A
exacerbate disease severity [9,12]. Further evidence from
models of inflammatory angiogenesis in the eye and more re-
cent models of UC have identified VEGF164 (165 in humans)
as the major pathological isoform of VEGF-A. This evidence
implicates VEGF164 driving inflammation through altered
vascular tone, leakage, remodeling, leukocyte recruitment
and changes in the sub endothelial extracellular matrix [13].
We have previously reported the in vitro ability of the
murine homologue of human VEGF165b, known as
VEGF164b (the main endogenous anti-angiogenic VEGF-A
isoform), to inhibit endothelial cell proliferation, migration
and changes in vessel permeability caused by VEGF-A [14].
Based on our results, we examined the potential thera-
peutic application of this endogenous inhibitor of VEGF-A
signaling in an in vivo model of experimental UC. We
hypothesized that since rVEGF164b should block blood
vessel formation and reduce disease activity by interfering
with VEGF-A signaling in our model of UC that it would
also diminish evidence of inflammatory injury. We found
that rVEGF164b attenuated disease activity, reduced blood
and lymphatic vessel formation, and inhibited several
markers of disease. Our findings suggest that shifts in
VEGF isoform expression may regulate UC activity, indi-




As previously described [14], a 570 base pair coding se-
quence of mouse VEGF164b cDNA was synthesized
(GeneScript; Piscataway, NJ) to omit a single arginine
residue at the COOH terminal of the murine VEGF164b
resulting in rVEGF164b. The rVEGF164b cDNA was sub
cloned into the adenovirus shuttle vector pAdenoVator
CMV5 (MP Biomedicals; Solon, OH). A shuttle vector
containing the rVEGF164b coding sequence was linea-
rized with PacI, and co-transformed with pAdenoVator
ΔE1/E3 (containing the adenovirus backbone sequence)
into the E. coli strain BJ5183 for homologous recombi-
nation. After isolation of recombinants from positive
clones, an adenovirus vector Ad5-CMV-rVEGF164b, was
rescued by transfection of PacI linearized plasmid DNA
into the HEK293 packaging cell line.
Induction of TNBS colitis
All procedures were approved by the LSUHSC Institu-
tional Animal Care and Use Committee (IACUC) underNIH and USDA guidelines. TNBS colitis was induced
using a modified version of the protocol of Morris et al.
[15]. In this model, BALB/c mice were anaesthetized by in-
traperitoneal injection of Ketamine/Xylazine and were
checked for sedation by toe pinch stimulation. Ethanol
(100 μL of 10% v/v in water) containing 2 mg of TNBS
(Sigma-Aldrich; St. Louis, MO) was slowly introduced into
the colon using a rubber tipped gavage needle inserted
5 cm from the anus. Animals receiving vehicle alone (10%
ethanol) were dosed in the same fashion. TNBS and vehicle
were administered every seventh day resulting in a cyclical
disease pattern. The Ad5-CMV-rVEGF164b (1 × 10
11 viral
particles) was administered once daily for three days before
the induction of TNBS colitis to maximize effect of the re-
combinant protein. Animals were euthanized at day 3
(acute phase; n = 5) and day 21 (chronic phase; n = 5).
Measurement of VEGF-A isoforms
Serum and tissue levels of VEGF-A isoforms were
measured by mouse VEGF-A ELISA (R&D Systems;
Minneapolis, MN) in both the TNBS (BALB/c) and DSS
(C57BL/6) models of UC at days 7 and 10. Serum levels
of VEGF-A isoforms were measured using 5 μL of serum
collected in serum separator tubes (BD; Franklin Lakes,
NJ). Tissues were homogenized in ice cold PBS
containing protease inhibitors (Sigma-Aldrich) followed
by removal of the insoluble fraction by centrifugation at
10,000 × g for 15 min. Total protein level was adjusted
to load a final concentration of 10 ng/well.
Measurement of occult blood, stool form and weight loss
to determine disease activity
Disease activity index is defined as a composite score of
severity in weight loss, presence of occult blood in stool,
and aberrant stool form. The score for each category is
added together and divided by 3, which generates an
average index of the contribution of each aspect of dis-
ease to overall score. Occult blood was measured by ap-
plying a thin smear of fresh fecal matter to a ColoScreen
test card (Helena Laboratories; Beaumont, TX) and
adding a drop of color change reagent. Fecal blood levels
were graded on a 0–4 scale based on the following color
changes: 0, no change; 1, slight change (random light
blue speckled pattern); 2, moderate change (solid light
blue smeared pattern); 3, severe change (solid dark blue
smeared pattern); and 4, surface blood. Stool form was
measured by grading stool shape and deformation under
pressure. Stool was graded using a 0–4 scale based on: 0,
fully formed dry stool; 1, fully formed moist stool; 2, fully
formed soft stool; 3, unformed soft stool; and 4, diarrhea.
These scores were summed with weight change (1, > −5%
weight change; 2, > −10% weight change; 3, > −15% weight
change; 4, < −20% weight change) and divided by 3 to
create a weighted disease activity index score.
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After the animals were euthanized, tissue from the colon
to the cecum was removed. The tissue lengths were mea-
sured from the junction of the cecum and colon to the
anus, afterwards the cecum and feces were removed from
the colons and the weights were determined. A length to
weight ratio was calculated as colon weight (in mg) divided
by colon length (in cm). The colons were divided into 4
sections, and the most distal section fixed in 1% parafor-
maldehyde. The remaining 3 sections were frozen for fur-
ther processing. Livers, kidneys, lungs and spleens were
removed, weighed, and examined my histopathological
analysis to gauge any adenovirus-mediated inflammation.
MPO assay
The proximal most sections of the colon were homoge-
nized in HETAB buffer, subjected to 3 freeze thaw cycles,
and adjusted to a protein concentration of 20 mg/mL. The
homogenates were centrifuged at 10,000 × g for 15 min
and the supernatants were used for the MPO assay at
50 ng/μL total protein per well. Protein samples were in-
cubated with 150 μL of 0.17 mg/mL o-dianisidine
suspended in potassium phosphate buffer pH 6.0 with
0.001% H2O2. Color change was measured after 20 min at
470 nm on a MCC340 microplate reader (Finstruments;
Helsinki, Finland).
Protein content of TNBS colitis serum
Blood samples were harvested at days 3 and 21. Serum
was separated by centrifugation in serum separator tubes
(BD) at 8,000 rpm for 90 sec followed by diluted to a
working concentration with water (10×). Protein content
was measured using a Bio-Rad DC protein assay kit fol-
lowing the protocol for microplates. Data was normal-
ized to control and significance was determined by
ANOVA with Dunnett’s post test.
Histopathology/Measurements
Histopathology was measured by blinded scorers based
on area involved in inflammation (0–4), crypt damage
and loss (0–4), edema (0–3), follicular aggregates (0–3),
surface erosion (0–3) and mononuclear cell and poly-
morphonuclear cell infiltration (0–3). Scores for each
category were combined to give an overall histopath-
ology score. In addition, total follicle aggregates
containing a mixture of lymphocytes and leukocytes in-
cluding macrophages were identified by histopathology
and counted. Sections were stained by immunohisto-
chemistry for Mac-2 (Accurate Chemicals, Westbury,
NY) to confirm the structures contained macrophages.
Blood vessel/Lymph vessel staining and counting
Slides of distal colon were deparaffinized in xylene and
graded alcohol and followed by antigen retrieval incitrate buffer under steam for 20 min followed by
defixation in 0.01% sodium borohydride for 20 min and
were peroxide quenched in 90% methanol containing 3%
H2O2 for 20 min. Sections for counting were blocked in
10% goat serum in PBS for 1 h followed by incubation in
primary antibody for blood vessels at 1:200 anti-MECA32
or lymphatic vessels 1:200 anti-VEGFR-3 (eBioscience;
San Diego, CA) diluted in antibody amplifying dilution
buffer (PRO Histo; Columbia, SC) overnight at 4°C. Slides
were washed in antibody amplifying wash buffer (PRO
Histo) followed by incubation in a biotin conjugated sec-
ondary cocktail for 2 h and washed and then incubated in
streptavidin HRP for 30 min and washed. Slides were de-
veloped using DAB (Dako; Glostrup, Denmark) and
counterstained with hematoxylin.
Vessel counting
Vessels (blood and lymphatic) were counted in 3 un-
damaged colon sections per slide that had been stained
for MECA-32 (blood vessels) and VEGFR3 (lymphatic
vessels) at 40× magnification on an Olympus BX50
microscope (Olympus; Center Valley, PA). The same
procedure was carried out for both acute and chronic
samples by a blinded counter and the resulting data was
analyzed by ANOVA.
Statistical analysis
Statistics were performed using the Instat software pack-
age (Scottsdale, AZ). All data was analyzed by ANOVA
with Dunnett’s post testing to determine significant dif-
ference (p < 0.05) from control. A two-tailed Student’s t
test was performed on data to determine significant dif-
ference (p < 0.05) between VEGF164b treated and un-
treated animals.
Results
Measurement of VEGF serum levels in TNBS and DSS models
of colitis
Increased serum VEGF-A has been documented in ac-
tive human UC and in many animal models of UC.
Thus, we determined serum levels of VEGF-A in both
TNBS and DSS models of UC to determine which model
could best represent human UC. Using a VEGF ELISA
we found that our model of TNBS colitis had signifi-
cantly elevated VEGF-A in the serum (16.2-fold) com-
pared with vehicle-treated animals (Figure 1A). In
contrast, we could not detect a statistical difference in
serum VEGF-A levels between control and DSS treated
mice (Figure 1B). Interestingly, there was also a strain
difference in basal VEGF-A expression levels between
C57BL/6 mice and BALB/c mice, with 5.8-fold more
VEGF-A in the serum of control C57BL/6 mice (74.09 ±
19.82 pg/mL) compared with BALB/c mice (13.70 ±
0.01 pg/mL). These data agree with work by Chidlow
Figure 1 Measurement of serum levels of VEGF in the TNBS and DSS models of UC. The level of total serum VEGF-A isoforms was measured
by ELISA in serum from control, vehicle, and TNBS treated mice (A); n = 4. The level of total serum VEGF-A isoforms was measured by ELISA in serum
from control and DSS treated mice (B); n = 4. Serum protein was measured at either the acute (C) or chronic stages of the model (D); n = 5. Levels of
total serum VEGF-A isoforms was measured in serum of animals treated with Ad5-CMV-rVEGF164b at 7 days after injection of Ad5-CMV-rVEGF164b
using doses of 0 (control), 1 × 107, 1 × 109, and 1 × 1011 viral particles (E). An estimate of the persistence of expression of rVEGF164b was generated by
measuring total serum VEGF-A isoforms in the serum of animals injected with 1 × 1011 viral particles of Ad5-CMV-rVEGF164b at days 0, 10, and 21 (F).
Cromer et al. Journal of Translational Medicine 2013, 11:207 Page 4 of 12
http://www.translational-medicine.com/content/11/1/207et. al. [11], suggesting the TNBS model of UC was most
appropriate for our study. Another important clinical
marker of UC is developing protein losing enteropathy
(PLE), representing the loss of serum protein content into
the intestine. In our model of TNBS colitis using 10%
ethanol we did not observe significant protein loss when
measuring total protein levels of serum at either acute
(Figure 1C) or chronic (Figure 1D) time points. This result
may reflect a different form of injury or severity of injury
compared with the DSS or other models of UC.
Expression VEGF in TNBS and DSS models of colitis
We previously characterized the ability of VEGF164b to
inhibit endothelial cell proliferation, migration and
changes in vessel permeability in vitro caused by VEGF-A
[14]. We generated an adenoviral vector (Ad5-CMV-
rVEGF164b) expressing a murine recombinant VEGF164b(rVEGF164b) and showed that rVEGF164b blocks the ef-
fect of VEGF-A to stimulated proliferation, barrier
dysregulation and cytoskeletal rearrangement of murine
microvascular endothelial cells (MVECs). These findings
are significant since these effects could result in inhibiting
new vessel formation and vessel leakage in vivo. Excessive
vessel formation and permeability are key markers of in-
flammation, and correlate to the pathogenesis of many
diseases including UC. Based on these in vitro results we
examined the potential therapeutic application of this en-
dogenous inhibitor of VEGF-A signaling in a model of ex-
perimental UC in vivo. Currently, no specific antibodies
are available that can distinguish the VEGF164b isoform
of VEGF, from endogenous VEGF-A. Since VEGF-A and
rVEGF164b are both bound by anti-VEGF-A we estimated
the change in rVEGF164b production in response to
adenovirus based on the increase in total VEGF-A signal
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rVEGF164b. In this experiment, we measured total VEGF
isoforms by ELISA in serum of animals treated with Ad5-
CMV-rVEGF164b at 7 days after injection using doses of
1 × 107, 1 × 109 and 1 × 1011 viral particles (Figure 1E).
This analysis showed a significant increase in total VEGF-
A isoforms in mice administered 1 × 1011 viral particles of
Ad5-CMV-rVEGF164b compared with control (untreated)
mice. In addition, we generated an estimate of persistence
in rVEGF164b expression in the serum of animals injected
with 1 × 1011 viral particles at days 0, 10, and 21 (Figure 1F).
This was only an estimation of rVEGF164b expression, de-
termined by comparing total VEGF-A isoforms in serum
from Ad5-CMV-rVEGF164b treated mice to total VEGF-A
isoforms in serum from mice treated with an equivalent
dose of a control vector (Ad5-CMV-GFP). While mice
treated with Ad5-CMV-GFP showed no significant changeFigure 2 Assessment of disease progression in the TNBS model of UC
rVEGF164b, TNBS, and TNBS + Ad5-CMV-rVEGF164b treated mice. * denotes
that day. (A); n = 5. Colon length to weight ratio was determined in contro
day 3 (B) and day 21 (C) of disease. MPO assay results at day 3 (D) and da
TNBS, and TNBS + Ad5-CMV-rVEGF164b colons; n = 5. Shown are *p < 0.05,in total VEGF-A isoforms, mice treated with Ad5-CMV-
rVEGF164b showed a transient increased expression. This
increase was highest at day 10 and was decreased by day
21, a result typical of a non-replicative/non-integrating
adenovirus expression vector.
Assessment of DAI
We initially examined disease activity index (DAI), a
composite score of severity in weight loss, presence of
occult blood in stool, and aberrant stool form in control
mice, mice treated with Ad5-CMV-rVEGF164b, in TNBS
mice, and in TNBS mice treated with Ad5-CMV-
rVEGF164b (Figure 2A). TNBS treatment resulted in
significant elevation of DAI after day 1 that lasted the
duration of the experiment (21 days). Most of the in-
crease in DAI scores in TNBS treated mice was due to
elevated occult blood scores and stool form scores with. Disease activity index (DAI) was determined in control, Ad5-CMV-
significant differences between treated and untreated TNBS mice on
l, Ad5-CMV-rVEGF164b, TNBS, and TNBS + Ad5-CMV-rVEGF164b mice at
y 21 (E) in disease were determined from control, Ad5-CMV-rVEGF164b,
**p < 0.005.
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Control mice that received Ad5-CMV-rVEGF164b alone
had no significant changes in DAI. However, TNBS mice
that received Ad5-CMV-rVEGF164b showed significant
protection at several days (including days 6, 10, 11, 13,
15, 17 and 19–21) as determined by Student’s t-test ver-
sus untreated TNBS mice (Figure 2A). The Ad5-CMV-
rVEGF164b treated TNBS mice also recovered faster
after each subsequent TNBS injection compared with
untreated TNBS mice. These data suggest that reduced
VEGF-A signaling by treating mice with Ad5-CMV-
rVEGF164b inhibited the TNBS mediated mechanisms
that sustain inflammation.
Determination of colon length, weight, and LXW ratio
As colitis progresses, the length of the colon becomes
shorter and it becomes thicker in circumference as the
muscles of the colon contract. These factors serve as
clinical markers for the progression of chronic inflam-
mation in UC [16]. The ratio of the colon length and
weight (LXW) is commonly used to determine levels of
inflammation in models of UC. In the TNBS model at
day 3 we found no significant alterations in either colon
length or weight (Figure 2B) while at day 21 we found
that TNBS increased the colon LXW score (55.4% ±
7.7%) compared with control. Interestingly, rVEGF164b
treatment reduced the LXW significantly in TNBS mice
to 37.2% ± 2.3% above control scores (Figure 2C). The
reduction of LXW ratio score in TNBS shows that
inhibiting VEGF-A signaling by rVEGF164b treatment
can effect gross, clinically relevant measurements of
chronic inflammation in the colon.
Immune cell infiltration in the colon
MPO activity was used as an indirect measurement of
neutrophil infiltration in the colon, which is an impor-
tant measurement of acute inflammation in the tissue.
We observed that at day 3, the rVEGF164b treatment
significantly reduced MPO activity in the colons of
TNBS mice compared with untreated TNBS mice, while
treatment had no effect on the MPO level in control ani-
mals (Figure 2D). Interestingly, the MPO activity at day
21 in TNBS mice treated with rVEGF164b was reduced
to levels in control mice. However, the MPO activity in
untreated TNBS animals remained significantly elevated
compared with control levels (Figure 2E). These results
suggest that rVEGF164b treatment has effects on acute
as well as chronic markers of inflammation in our model
of TNBS colitis.
In sections of colon we identified follicle aggregates
containing a mixture of lymphocytes and leukocytes by
histopathological examination (Figure 3A). These sec-
tions were immunostained for expression of macrophage
subpopulation-specific antigen (Mac-2) to confirm thestructures contained macrophages (Figure 3B). Interes-
tingly, the elevation in the number of follicle aggregates
(which are a sign of increased immune activity in the
colon) induced by TNBS treatment was reduced by
rVEGF164b treatment to control levels at both the acute
(Figure 3C) and chronic (Figure 3D) phases of TNBS [17].
Evaluation of blood vessel/lymphatic vessel density
The reduction in inflammatory scores may be explained
by inhibiting blood vessel formation. This inhibition in
turn, could reduce the area of inflamed and permissive
endothelium available to recruit cells from the circula-
tion as well as reduce blood vessel permeability leading
to less loss of fluid from the vessels into the adjacent tis-
sue. To quantify changes in blood vessel density, we
stained slides of colon sections from untreated control
mice (Figure 4A), TNBS treated mice (Figure 4B), Ad5-
CMV-rVEGF164b treated mice (Figure 4C), and TNBS +
Ad5-CMV-rVEGF164b treated mice (Figure 4D) with
antibodies against a marker of blood vessels (MECA32).
Subsequently, we counted the number of positively
staining blood vessels in each section. The number of
blood vessels per section of colon in TNBS mice in-
creased significantly to 2.0-fold compared with control
mice as early as day 3 (Figure 4E) during the acute phase
of inflammation and was maintained at 2.1-fold higher
over control mice on day 21 (Figure 4F). The
rVEGF164b treatment did not completely block angio-
genesis, but it did reduce angiogenesis significantly at
both time points in TNBS mice. This result correlates
with data on colon LXW, MPO and histopathology,
suggesting that while angiogenesis may be one of many
driving factors in UC, it is responsible for increased tis-
sue area affected, immune cell infiltration, and disease
severity that make up the complex etiology of UC.
To quantify changes in lymphatic vessel density, we
stained slides of colon sections from untreated control
mice (Figure 5A), TNBS treated mice (Figure 5B), Ad5-
CMV-rVEGF164b treated mice (Figure 5C), and TNBS +
Ad5-CMV-rVEGF164b treated mice (Figure 5D) with
antibodies against markers of lymphatic vessels (VEGFR-
3). Afterwards, we quantified the number of positively
staining lymphatic vessels in each section. In the stained
sections, we observed a decrease in lymphangiogenesis
by rVEGF164b treatment in TNBS mice (Figure 5E and
5F), which was proportional to the decrease in angio-
genesis. This result may suggest a direct link between
angiogenesis and lymphangiogenesis in the TNBS model
of UC.
Analysis of histopathology changes
We examined the effect of rVEGF164b treatment on his-
topathologic changes in disease progression using the
TNBS model of UC, by comparing untreated control
Figure 3 Determination of lymphoid follicle aggregates in the TNBS model of UC. Representative image (10× magnification) shows
detailed composition of follicle aggregate in TNBS treated colon (A). Representative image (40× magnification) of follicle aggregate showing
staining for Mac-2 positive cells (arrows) (B). The number of follicles were quantified at day 3 (C) and 21 days (D) of disease; n = 5.
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CMV-rVEGF164b treated mice (Figure 6C), and TNBS +
Ad5-CMV-rVEGF164b treated mice (Figure 6D). We
quantified the histopathologic changes as overall histo-
pathology scores; these data showed the TNBS mice
scored significantly higher than control mice in edema,
inflammatory cell infiltration and area involved (Figure 6E
and 6F). However, there was significant protection
with Ad5-CMV-rVEGF164b treatment in TNBS indu-
ced UC at both the acute and chronic phases of
inflammation.
Discussion
Angiogenesis occurring under pathological conditions
such as UC often results in inflammation driven by newly
formed and remodeled blood vessels. We hypothesized
that inhibition of VEGF-A signaling using the endogenous
inhibitor of VEGF-A signaling VEGF164b would reduce
injury resulting from inflammatory angiogenesis. In this
study we demonstrated significant protection from TNBS
induced colitis in VEGF164b treated animals. In the nor-
mal human colon the level of inhibitory VEGFs are 20 fold
higher than pro-angiogenic VEGFs suggesting over ex-
pression of VEGF164b in UC may restore a normal ba-
lance of VEGF-A mediated signaling [18]. In this study,
we demonstrated VEGF164b, the endogenous inhibitor of
VEGF-A signaling, is an ideal candidate for exploring the
role of this class of inhibitory VEGFs in the etiology of UC
and for possible therapeutic use.
TNBS treatment significantly elevated serum VEGF-A
levels compared with the DSS model of UC, which has
no difference in serum VEGF-A levels compared withcontrol mice. Interestingly, Chidlow et al. found no ele-
vation of VEGF-A levels in the DSS model of UC
[9,11,12]. In contrast, Scaldeferi et al. and Danese et al.
suggested that VEGF-A plays a pivotal role in DSS colitis
[9,11,12]. We found that tissue levels of VEGF-A were
elevated in both DSS and in TNBS models (data not
shown), but that serum levels of VEGF-A were only sig-
nificantly affected in TNBS colitis. Based on these find-
ings we selected the TNBS model in BALB/c mice to
give the highest possible contribution of VEGF-A to-
wards gut inflammation as is suspected in human UC.
In the typical TNBS model of colitis, TNBS is dissolved
in 20% ethanol, which destroys the epithelial layer allowing
greater penetration of the TNBS hapten. However, we used
10% ethanol. Ethanol is known to induce many pro-
angiogenic growth factors and receptors including VEGF,
basic fibroblast growth factor (bFGF), transforming growth
factor β (TGF-β), VEGF receptor 1 and VEGF receptor 2
resulting in angiogenesis not mediated by immune inflam-
matory mechanisms. Therefore, reducing the concentra-
tion of ethanol creates a more accurate representation of
the role of VEGF-A in colitis [19]. Although the concentra-
tion of ethanol was lower in our model it was sufficient to
disrupt the epithelial barrier and allow TNBS to initiate
immune mediated inflammation and significant elevation
of disease activity. Animals treated with rVEGF164b were
found to recover faster after each subsequent TNBS ad-
ministration and maintain an average level of disease
activity less than that of the untreated animals.
Our previous work has shown that rVEGF164b
inhibited endothelial proliferation and migration, two of
the most important processes in new vessel formation
Figure 4 Evaluation of blood vessel density in the TNBS model of UC. Representative images of colon sections (20× magnification) are
shown from control (A), TNBS (B), Ad5-CMV-rVEGF164b (C) and TNBS + Ad5-CMV-rVEGF164b (D) mice immunostained with stained with MECA-32.
Angiogenesis was quantified at day 3 (E) and day 21 (F) of disease; n = 5.
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expansion of the blood vascular system in the colon in-
duced by TNBS treatment. However, there was still a
modest increase in blood vessel density which may rep-
resent VEGF-A independent angiogenesis. We can infer
the angiogenesis seen in our model is VEGF-A inde-
pendent because the estimated level of rVEGF164b ex-
pression that was detected far exceeded the level of
VEGF-A in the serum. In addition, we have previously
reported that rVEGF164b can completely inhibit VEGF-
A signaling at concentrations 10-fold lower than VEGF-
A concentrations used in experiments [14].
One of the most interesting findings in this report was the
reduction of the level of TNBS induced lymphangiogenesis
by rVEGF164b administration is comparable to the reduc-
tions in angiogenesis. Lymphangiogenesis was increased in
proportion to angiogenesis by TNBS which is in contrast to
DSS colitis where levels of lymphangiogenesis are much
higher than angiogenesis [20]. In fact, many reports havedescribed the link between blood and lymphatic prolifera-
tion in several pathologies that have over expression of
VEGF-A including cancer. While the exact relationship is
unknown there are several possibilities for this observation
[21-23]. First, VEGF-A over expression can drive the expres-
sion of VEGF-C and VEGF-D both of which are potent pro-
moters of lymphangiogenesis resulting in functional vessels.
Second, VEGF-A acting directly on lymphatic endothelium
through VEGF receptor 2 can cause proliferation of lym-
phatic EC leading to overly large vessels that are deficient in
pumping and result in edema. Third, VEGF-A can indirectly
recruit lymphangiogenic lymphocytes through alterations of
the blood vessels adhesive properties (CAM expression).
Without further studies we cannot say with certainty what
role rVEGF164b plays in reducing lymphatic vessels. We are
currently investigating these questions to determine any fur-
ther potential benefits of rVEGF164b therapy.
This study found that many of the markers of inflam-
mation in UC (histopathology, neutrophil infiltration,
Figure 5 Evaluation of lymphatic vessel density in the TNBS model of UC. Representative images of colon sections (20× magnification) are
shown from control (A), TNBS (B), Ad5-CMV-rVEGF164b (C) and TNBS + Ad5-CMV-rVEGF164b (D) mice immunostained with VEGFR-3.
Lymphangiogenesis was quantified at day 3 (E) and day 21 (F) of disease; n = 5.
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etc.) were correlated with the level of angiogenic inhi-
bition, and could be attenuated if not completely
blocked by rVEGF164b treatment. Disease activity and
histopathology of rVEGF164b treated animals revealed
significantly less damage to the colon compared with
untreated TNBS animals. Most of the decrease in DAI
was due to reductions in occult blood and stool form.
This result suggests there was less vascular leak due ves-
sel permeability inhibition, reduced vessel damage, and
less epithelial and mucosal damage, which cumulatively
would affect these parameters. Of particular note to DAI
is that at early stages (acute) of inflammation, DAI in
treated and untreated animals receiving TNBS was sta-
tistically the same while other scores (MPO, follicle ag-
gregate) were reduced. This may be due to exaggerated
effects of mechanical damage by insertion of the enema
needle on occult blood or anesthesia on weight loss,masking the effects of rVEGF164b on DAI in the early
stages of inflammation. Therefore, it may be more suit-
able to use the alternative methods of examining inflam-
mation we employed to draw conclusions about the
effects of rVEGF164b on the acute phase of TNBS col-
itis. In this case, histopathology examination revealed
that area involved, edema, inflammatory cell infiltration,
and crypt loss were higher in untreated TNBS animals
compared with rVEGF164b treated animals at both 3
and 21 days. Although these individual scores were not
significant individually, overall histopathology scores re-
vealed a significant elevation in colon damage. Gross
measurements of the colon revealed significant protec-
tion by rVEGF164b, which may be attributed to a lack of
edema and reduced enlargement and contraction of the
muscularis mucosae. The lack of edema may be directly
linked to the anti-permeability as well as anti-angiogenic
effects of rVEGF164b, permitting the lymphatic system
Figure 6 Analysis of histopathology changes in the TNBS model of UC. Histopathology was scored by 2 blinded scorers on 6 parameters.
Representative images of hematoxylin and eosin stained sections (20× magnification) are shown from control (A), TNBS (B), Ad5-CMV-rVEGF164b
(C) and TNBS + Ad5-CMV-rVEGF164b (D) treated mice. Histopathology scores for colons on day 3 (E) and day 21 (F) of disease were combined
from both blinded scorers; n = 5.
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fected by rVEGF164b in protection against colon shor-
tening, suggesting that this anti-angiogenic VEGF has
many extensive and unanticipated anti-inflammatory
properties [16].
The rVEGF164b treatment had a profound inhibitory
effect on recruiting inflammatory cells to the colon in
TNBS mice. This result may be due to reduced vessels/
endothelial area, preservation of endothelial junction,
and/or reduced adhesion molecule expression mediated
by VEGF-A signaling [14,24-26]. MPO activity, a meas-
urement of neutrophil infiltration into the tissue, was
significantly reduced by rVEGF164b in TNBS treated an-
imals. This reduction was similar in magnitude to the
decrease in angiogenesis and may represent reduction in
VEGF-A activity on the endothelium. VEGF-A is one of
the most important factors in IBD for recruiting neutro-
phils [24], the major source of MPO in tissues.Interestingly, MPO activity was significantly reduced at
day 21 in rVEGF164b treated animals despite the declin-
ing expression pattern of rVEGF164b at this time point.
In fact, the overall MPO score was much lower at day
21 than at day 3, even in animals treated with TNBS
alone. This is likely because day 21 represents a late
(recovery) phase of inflammation after the initial TNBS
insult, in which most of the neutrophils have migrated
away from the injured tissue. In addition, the rVEGF164b
treated animals showed reduced primary tissue injury
leading up to the late (recovery) phase. Therefore these
mice likely recovered from the injury faster than non-
treated animals and would have subsequently less neu-
trophil infiltration.
Unlike many features of this model, the increase in fol-
licle aggregates was completely blocked despite an in-
complete blockade of angiogenesis. This could possibly
be due a combination of reduction in the number of
Cromer et al. Journal of Translational Medicine 2013, 11:207 Page 11 of 12
http://www.translational-medicine.com/content/11/1/207blood and lymph vessels and changes in the adhesive
properties of the vessels, which mediate forming these
structures. In addition, the formation of follicle aggre-
gates heavily relies on recruiting macrophages to expand
these structures, and VEGF-A is the most potent
chemoattractant for this cell type [27,28]. This observa-
tion suggests that VEGF164b may have many more
beneficial mechanisms apart from those acting directly
on the vasculature.
Many treatments of UC such as TNF-α inhibitory anti-
bodies and mesalamine have indirect effects endothelial
cells. Only one current treatment with natalizumab, ad-
dresses one of the many roles the microvasculature plays
in UC [29-33]. The current standards for biological treat-
ment of UC are TNF-α inhibitors (e.g., Infliximab,
Humera, etc.), which are effective clinically and in several
animal UC models (including the TNBS model). It is diffi-
cult to compare the models of TNBS used in the studies
of TNF inhibitors to our model given the adaptations that
were used to reduce non-specific growth factor induction.
However, it is interesting to note the trend of incomplete
inhibition of disease activity was observed in TNBS mice
treated with Infliximab, and many of the results that we
obtained with rVEGF164b treatment were similar.
Conclusions
This is the first report using an endogenous inhibitory
VEGF-A isoform in a model of experimental colitis. In this
study we found the markers of UC disease showed im-
provements proportional to or greater than the level of an-
giogenic blockade that rVEGF164b treatment provided. Our
results confirm the pivotal role of the inflamed intestinal
microvasculature in initiating and propagating gut inflam-
mation. We also found that rVEGF164b treatment signifi-
cantly inhibited the level of lymphangiogenesis in our UC
model. However, further studies are necessary to examine
the role of rVEGF164b on this component of UC involving
changes in lymphatic proliferation, structure and function.
Although we do not yet know how VEGF-A and VEGF164b
ratios change during active gut inflammation, VEGF164b
does appear to represent a new marker of disease with im-
portant bioactivity against VEGF-A mediated inflammation,
angiogenesis (and lymphangiogenesis). VEGF164b treat-
ment has potential for further use investigating the role of
these endogenous inhibitors of angiogenesis in UC. These
results also show treatment with VEGF164b as a promising
new avenue for therapy in UC. Our future work will investi-
gate potential VEGF164b treatment in mice that already
have developed TNBS-induced colitis.
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